文献速递免疫规划

自组装单价脂化甘露糖配体作为独立纳米佐剂

Self-assembled monovalent lipidated mannose ligand as a standalone nanoadjuvant.
PubMed 文献 · Vaccine · 2024-06-18

本研究评估甘露糖-脂肽配体增强聚亮氨酸(L15)-抗原偶联物锚定脂质体疫苗免疫原性的能力,抗原为A组链球菌(GAS)B细胞表位J8联合通用T辅助表位PADRE(P)。配体3(含甘露糖、甘氨酸/赖氨酸间隔子和两个棕榈酸)诱导的IgG滴度显著高于非甘露糖化脂质体,阳离子脂质体进一步增强IgG滴度,产生的抗体能杀死GAS细菌。仅配体3与PJ8物理混合自组装成纳米棒,诱导的抗体滴度与先导脂质体配方及强效但有毒性完全弗氏佐剂(CFA)相当,且抗体调理作用更强,未诱导可观察的不良反应或过度炎症反应。

要点

  • 配体3(甘露糖-甘氨酸/赖氨酸间隔子-双棕榈酸)修饰脂质体诱导的IgG滴度显著高于非甘露糖化脂质体。
  • 阳离子脂质体可显著增强IgG滴度,产生的抗体能杀死GAS细菌。
  • 仅配体3与PJ8物理混合自组装纳米棒,抗体滴度与先导脂质体及CFA+PJ8相当,调理作用更强。

核心结论

  • 甘露糖配体3单独即可作为有效的疫苗纳米佐剂,诱导高滴度功能性抗体且无CFA样毒性。

研究设计与样本

  • 实验研究,评估六种甘露糖配体掺入中性脂质体(携带L15PJ8)的免疫原性,抗原为GAS B细胞表位J8联合PADRE(P)。

主要发现

  • 配体3(含甘露糖、甘氨酸/赖氨酸间隔子和两个棕榈酸)诱导的IgG滴度显著高于非甘露糖化脂质体。
  • 阳离子脂质体使IgG滴度显著增强,产生的抗体能杀死GAS细菌。
  • 仅配体3与PJ8物理混合自组装成纳米棒,诱导的抗体滴度与先导脂质体配方及CFA+PJ8相当。
  • PJ8+3免疫产生的抗体调理作用强于CFA+PJ8诱导的抗体。
  • 与CFA不同,配体3未诱导可观察的不良反应或过度炎症反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Subunit vaccines require an immunostimulant (adjuvant) and/or delivery system to induce immunity. However, currently, available adjuvants are either too dangerous in terms of side effects for human use (experimental adjuvants) or have limited efficacy and applicability. In this study, we examined the capacity of mannose-lipopeptide ligands to enhance the immunogenicity of a vaccine consisting of polyleucine(L15)-antigen conjugates anchored to liposomes. The clinically tested Group A Streptococcus (GAS) B-cell epitope, J8, combined with universal T helper PADRE (P) was used as the antigen. Six distinct mannose ligands were incorporated into neutral liposomes carrying L15PJ8. While induced antibody titers were relatively low, the ligand carrying mannose, glycine/lysine spacer, and two palmitic acids as liposomal membrane anchoring moieties (ligand 3), induced significantly higher IgG titers than non-mannosylated liposomes. The IgG titers were significantly enhanced when positively charged liposomes were employed. Importantly, the produced antibodies were able to kill GAS bacteria. Unexpectedly, the physical mixture of only ligand 3 and PJ8 produced self-assembled nanorods that induced antibody titers as high as those elicited by the lead liposomal formulation and antigen adjuvanted with the potent, but toxic, complete Freund's adjuvant (CFA). Antibodies produced upon immunization with PJ8 + 3 were even more opsonic than those induced by CFA + PJ8. Importantly, in contrast to CFA, ligand 3 did not induce observable adverse reactions or excessive inflammatory responses. Thus, we demonstrated that a mannose ligand, alone, can serve as an effective vaccine nanoadjuvant.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nahar UJ, Wang J, Shalash AO, et al. Self-assembled monovalent lipidated mannose ligand as a standalone nanoadjuvant. Vaccine. 2024. PMID: 38897890. doi:10.1016/j.vaccine.2024.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。